Table 2.
Clinical changes from baseline (verum versus placebo).
| aMepolizumab13 | Omalizumab14 | Dupilumab15 | Mepolizumab16 | |
|---|---|---|---|---|
| TPSs' mean reduction(SD) (verum/placebo) | 1.3 (1.72)/0.00 (1.72)，p = 0.028 | 2.67 (p = 0.001)/0.12 (p = 0.99) | 1.9 (1.2–2.5)/0.3 (0.4–1.0) (LS mean, 95% CI), p < 0.001 | 1.9 (1.4–2.4)/0.7(0.2–1.2) (LS mean, 95%CI)b, p ≤ 0.05 |
| Lund-Mackay CT scan score mean reduction (verum/placebo) | Any improvement: 10/2 patients | 4.0 (p = 0.02)/-0.5 (p = 0.10) | 9.1/0.2 (LS mean) (p < 0.001) | NR |
| SNOT-22 score reduction (verum-placebo) | NR | NR | 18.1 (10.6–25.6) (LS mean, 95%CI), (p < 0.001) | 13.2 (4.2–22.2) (LS mean, 95%CI), (p = 0.005) |
| UPSIT or loss of smell symptom score | Improved (Not significant) | Improved (p = 0.004) | Improved (p < 0.001) | Improved (p < 0.001) |
| Nasal congestion or obstruction | Improved (Not significant) | Improved (p = 0.002) | Improved (p < 0.001) | Improved (p = 0.002) |
| Anterior rhinorrhea | No improvement | Improved (p= 0.003) | Improved (AM, p < 0.0001; PM, p = 0.0008) | Improved (p < 0.001) |
| Postnasal drip or mucus in the throat | Improved (not significant) | NR | Improved (AM, p = 0.002) | Improved (p < 0.001) |
| SF-36 | NR | Physical health score Improved (p= 0.02) | NR | NR |
| RSOM-31 | NR | Sleep improved (p = 0.03), general symptoms improved (p = 0.01). | NR | NR |
| AQLQ or ACQ5 reduction | NR | AQLQ Improved (p = 0.003) | ACQ5 Improved (p < 0.001) | NR |
| PnIF improvement (verum-placebo) L/min | Improved (not significant) | NR | 33.1 (12.7–53.5), (LS mean, 95% CI) (p = 0.002) | 26.7 (3.1–50.2) (LS mean, 95% CI) (p = 0.027) |
| FEV1% predicted (verum/placebo) | NR | NR | 1.9/9.0, (LS mean) (p = 0.04) | FEV1 (L), not significant |
TPS, total nasal endoscopic polyp score; LS, least squares; CI, confidence interval; NR, not reported; SNOT-22, Sino-nasal Outcome Test; UPSIT, University of Pennsylvania Smell Identification Test; SF-36, 36-Item Short Form Survey; RSOM-31, 31-Item Rhinosinusitis Outcome Measuring Instrument; AQLQ, Asthma Quality of Life Questionnaire; ACQ5, 5-item Asthma Control Questionnaire; PnIF, Peak Nasal Inspiratory Flow; FEV1, forced expiratory volume 1. NR, not reported.
Because of the dropouts, the shown data of this study were all last-observation-carried-forward imputation (LOCF) results.
The TPSs were conversed from the corresponding figure in published articles by using WebPlotDigitizer v4.1.